Previous 10 | Next 10 |
WATERTOWN, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the appointment of Karen Zaderej ...
WATERTOWN, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the election of Anthony (Tony) Ad...
China's National Medical Products Administration approved EyePoint Pharmaceuticals (NASDAQ:EYPT) and OcuMension Therapeutics' (OTCPK:OCUTF) intravitreal implant Yutiq to treat chronic non-infectious uveitis affecting the posterior segment of the eye. Uveitis is a type of eye inflamm...
WATERTOWN, Mass. and BEIJING, June 21, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, and OcuMension Therapeutics (HKS...
WATERTOWN, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that a late-breaking abstrac...
WATERTOWN, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executive...
EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2022 Earnings Conference Call May 04, 2022 08:30 AM ET Company Participants George Elston - CFO Nancy Lurker - President and CEO Jay Duker - COO Scott Jones - CCO Conference Call Participants Georgi Yordanov - Cowen Yatin Suneja - Guggenheim Securities...
EyePoint Pharmaceuticals (NASDAQ:EYPT) signed a license agreement with China-based Betta Pharmaceuticals to develop and commercialize EYP-1901 in Mainland China, Hong Kong, Macau and Taiwan (the Territory). EyePoint said it will retain global ophthalmic rights for EYP-1901 in the rest of the ...
EyePoint Pharmaceuticals press release (NASDAQ:EYPT): Q1 GAAP EPS of -$0.56 in-line. Revenue of $9.3M (+27.4% Y/Y) misses by $0.59M. Cash and investments at March 31, 2022 totaled $190.8 million compared to $211.6 million at December 31, 2021. We expect the cash ...
– Presented positive eight-month safety and efficacy data from ongoing DAVIO Phase 1 clinical trial for EYP-1901 in wet age-related macular degeneration (wet AMD) at Angiogenesis, Exudation, and Degeneration 2022; Phase 2 clinical trial expected to initiate in Q3 2022 – ...
News, Short Squeeze, Breakout and More Instantly...
EyePoint Pharmaceuticals Inc. Company Name:
EYPT Stock Symbol:
NASDAQ Market:
EyePoint Pharmaceuticals Inc. Website:
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 – – Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical tria...
WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company will host an R...